---
title: "Sionna Therapeutics, Inc. (SION.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SION.US.md"
symbol: "SION.US"
name: "Sionna Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T21:36:12.208Z"
locales:
  - [en](https://longbridge.com/en/quote/SION.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SION.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SION.US.md)
---

# Sionna Therapeutics, Inc. (SION.US)

## Company Overview

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.sionnatx.com](https://www.sionnatx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -20.71 | 505 | - | - | - |
| PB | 6.15 | 352 | 5.79 | 5.04 | 2.51 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-17T04:00:00.000Z

Total Analysts: **12**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 75% |
| Overweight | 1 | 8% |
| Underweight | 1 | 8% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 37.68 |
| Highest Target | 63.00 |
| Lowest Target | 23.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SION.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SION.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SION.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SION.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**